First Light Asset Management, LLC reported 28 positions worth $1.42B for the quarter ended Jun 30, 2026, up 51.9% on the prior quarter. It opened 2 new positions, added to 14, trimmed 12 and exited 5. Its largest holding is Neogenomics Inc at 12.6% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| ELVN Enliven Therapeutics, Inc. | +1.16M | +574.1% | $58.81M | 4.86% |
| SIBN SI-BONE, Inc. | +2.77M | +51.8% | $45.28M | 9.34% |
| TRVI Trevi Therapeutics, Inc. | +2.10M | – | $39.11M | 2.75% |
| NEO Neogenomics Inc | +2.55M | +26.2% | $37.20M | 12.62% |
| WGS GeneDx Holdings Corp. | +541.0K | +222.7% | $37.14M | 3.79% |
| TNDM Tandem Diabetes Care Inc | +2.07M | +157.4% | $31.22M | 3.6% |
| GH Guardant Health, Inc. | +161.3K | +57.5% | $24.20M | 4.67% |
| TCMD Tactile Systems Technology Inc | +462.6K | – | $13.78M | 0.97% |
| PCVX Vaxcyte, Inc. | +203.4K | +143.4% | $11.82M | 1.41% |
| SEPN Septerna, Inc. | +230.4K | +31.4% | $7.72M | 2.27% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| AXGN Axogen, Inc. | -1.25M | -31.3% | $57.94M | 8.94% |
| PVLA Palvella Therapeutics, Inc. | -208.9K | -21.3% | $31.92M | 8.31% |
| TWST Twist Bioscience Corp | -150.9K | -17.2% | $15.53M | 5.27% |
| WVE Wave Life Sciences, Inc. | -1.84M | -100.0% | $13.37M | Exited |
| VERA Vera Therapeutics, Inc. | -313.9K | -100.0% | $12.63M | Exited |
| MDXG Mimedx Group, Inc. | -2.84M | -100.0% | $11.23M | Exited |
| SGP SpyGlass Pharma, Inc. | -375.0K | -100.0% | $9.72M | Exited |
| ORGO Organogenesis Holdings Inc. | -3.50M | -100.0% | $8.29M | Exited |
| ESTA Establishment Labs Holdings Inc. | -61.2K | -19.9% | $5.25M | 1.49% |
| ATRC AtriCure, Inc. | -161.7K | -22.2% | $4.52M | 1.12% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | NEO Neogenomics Inc | Healthcare | 12.28M | $179.16M | 12.62% | +2.55M | +26.2% | Added | 9.47% |
| 2 | SIBN SI-BONE, Inc. | Healthcare | 8.13M | $132.65M | 9.34% | +2.77M | +51.8% | Added | 18.18% |
| 3 | AXGN Axogen, Inc. | Healthcare | 2.75M | $126.95M | 8.94% | -1.25M | -31.3% | Reduced | 5.12% |
| 4 | PVLA Palvella Therapeutics, Inc. | Healthcare | 771.9K | $117.96M | 8.31% | -208.9K | -21.3% | Reduced | 5.36% |
| 5 | TWST Twist Bioscience Corp | Healthcare | 727.9K | $74.89M | 5.27% | -150.9K | -17.2% | Reduced | 1.16% |
| 6 | ELVN Enliven Therapeutics, Inc. | Healthcare | 1.36M | $69.06M | 4.86% | +1.16M | +574.1% | Added | 1.86% |
| 7 | GH Guardant Health, Inc. | Healthcare | 441.6K | $66.25M | 4.67% | +161.3K | +57.5% | Added | 0.33% |
| 8 | MASS 908 Devices Inc. | Industrials | 6.28M | $54.66M | 3.85% | +210.2K | +3.5% | Added | 16.51% |
| 9 | AMLX Amylyx Pharmaceuticals, Inc. | Healthcare | 3.02M | $54.30M | 3.82% | -167.4K | -5.2% | Reduced | 2.71% |
| 10 | WGS GeneDx Holdings Corp. | Healthcare | 783.9K | $53.82M | 3.79% | +541.0K | +222.7% | Added | 2.64% |
| 11 | TNDM Tandem Diabetes Care Inc | Healthcare | 3.38M | $51.06M | 3.6% | +2.07M | +157.4% | Added | 4.87% |
| 12 | NPCE NeuroPace Inc | Healthcare | 2.86M | $45.46M | 3.2% | +401.2K | +16.3% | Added | 8.35% |
| 13 | EWTX Edgewise Therapeutics, Inc. | Healthcare | 1.10M | $44.50M | 3.13% | +93.3K | +9.3% | Added | 1.02% |
| 14 | ANAB Anaptysbio, Inc | Healthcare | 582.0K | $39.29M | 2.77% | +16.6K | +2.9% | Added | 2% |
| 15 | TRVI Trevi Therapeutics, Inc. | Healthcare | 2.10M | $39.11M | 2.75% | +2.10M | – | New | 1.34% |
Tip. Select a row to see that position’s full history at First Light Asset Management.
As of its Q2 2026 13F filing, First Light Asset Management, LLC’s five largest positions were Neogenomics Inc (NEO) at 12.6%, SI-BONE, Inc. (SIBN) at 9.3%, Axogen, Inc. (AXGN) at 8.9%, Palvella Therapeutics, Inc. (PVLA) at 8.3%, Twist Bioscience Corp (TWST) at 5.3% of the reported portfolio.
First Light Asset Management, LLC reported a 13F portfolio worth $1.42B across 28 positions for Q2 2026. That is up 51.9% from the previous quarter.
Its largest purchases by value were Enliven Therapeutics, Inc. ($58.81M), SI-BONE, Inc. ($45.28M), Trevi Therapeutics, Inc. ($39.11M). It opened 2 new positions.
Its largest sales by value were Axogen, Inc. ($57.94M), Palvella Therapeutics, Inc. ($31.92M), Twist Bioscience Corp ($15.53M). It exited 5 positions entirely.
From the Form 13F-HR reports First Light Asset Management, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.